Pegtarazimod holds promise for effectively treating acute exacerbations of COPD, a major unmet need in COPD treatment.

A doctor and patient both offer their perspectives on the challenges of returning home from the hospital after a COPD exacerbation.

On track to also complete enrollment in the Seabreeze STAT COPD study this month –– Expect to report topline data from Seabreeze STAT Asthma ...

Most chronic obstructive pulmonary disease (COPD) exacerbations were observed in those not treated with controller medications, but less than half of patients in the study received controller ...

—Theses investigators found an increased risk for both individual and composite cardiovascular events following exacerbations of COPD, with sustained risk after 1 year regardless of severity. Reviewed ...

Please provide your email address to receive an email when new articles are posted on . The FDA issued a warning in 2019 about serious breathing problems associated with gabapentinoids. The study ...

Mepolizumab significantly reduced the annualized rate of moderate or severe exacerbations in COPD with an eosinophilic phenotype. Some 20% to 40% of COPD patients have elevated blood eosinophil counts ...

Please provide your email address to receive an email when new articles are posted on . Risk estimation was based on area under the receiver operating characteristic curve, sensitivity and specificity ...

A research team from the LKS Faculty of Medicine at the University of Hong Kong (HKUMed) has highlighted recent advances in understanding and managing COPD, particularly in relation to its ...

A composition-of-matter patent (US 17/622,451, "A series of TLR2 agonist compounds") and A method-of-use patent for the treatment of rhinovirus-mediated exacerbations of chronic obstructive pulmonary ...

Patients with acute COPD exacerbations are seen frequently in the emergency department (ED). Acute exacerbations are associated with significant morbidity, mortality and health care expenditures.